These findings point to a specific GPR17 role in chemotactic guidance of stromal cells towards the ischemic sites and open to the hypothesis that the selective modulation of GPR17 signaling translates into beneficial treatments potentially reducing the extent of myocardial fibrosis and limiting the functional consequences of heart ischemia. The gene discussed is GPR17; the disease is Myocardial fibrosis.